Vanguard Global Advisers
BNTC icon

Vanguard Global Advisers’s Benitec Biopharma BNTC Stock Holding History

Vanguard Global Advisers’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Hold
8,660
– – ﹤0.01% 2717
2026
Q1 		$92.2K Buy
+8,660
New +$100K ﹤0.01% 2760

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Vanguard Global Advisers's BNTC Position: Q2 2026 in Review

Vanguard Global Advisers held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 8,660 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

Vanguard Global Advisers first reported a position in BNTC in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Vanguard Global Advisers held 8,660 shares of Benitec Biopharma worth $116K as of Q2 2026.
  • Vanguard Global Advisers left its Benitec Biopharma share count unchanged in Q2 2026.
  • Benitec Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2717 holding.
  • Vanguard Global Advisers first reported a position in Benitec Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.